STOCK TITAN
  1. Home
  2. News
  3. ZYNE

Zynerba Pharmace - ZYNE STOCK NEWS

Welcome to our dedicated page for Zynerba Pharmace news (Ticker: ZYNE), a resource for investors and traders seeking the latest updates and insights on Zynerba Pharmace stock.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) pioneers transdermal synthetic cannabinoid therapies for severe neurological conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.

Access timely reports on Zygel™ clinical trials for Fragile X syndrome and 22q11.2 deletion syndrome, FDA designations, and analysis of the Harmony Biosciences acquisition. Our curated news collection eliminates speculation while delivering actionable insights about ZYNE's novel therapeutic pipeline.

Key coverage areas: Phase 3 RECONNECT trial progress, orphan drug designation updates, partnership developments with Harmony Biosciences, and financial disclosures. All content maintains strict compliance with financial reporting standards and therapeutic research guidelines.

Bookmark this page for consolidated access to Zynerba's verified announcements. Monitor critical updates on synthetic cannabinoid advancements directly impacting treatment options for rare neuropsychiatric disorders.

News

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

Rhea-AI Summary
Harmony Biosciences completes acquisition of Zynerba Pharmaceuticals, expanding its portfolio with Zygel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

Rhea-AI Summary
Zynerba Pharmaceuticals reminds stockholders to tender their shares into the offer by Harmony Biosciences Holdings to purchase all outstanding shares of Zynerba common stock. The tender deadline is October 10, 2023, and stockholders will receive an up-front purchase price of $1.1059 per share plus one non-tradeable contingent value right per share. If all milestones are achieved, the total consideration payable to stockholders is up to $3.6503 per share in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
News

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

Rhea-AI Summary
Zynerba Pharmaceuticals urges stockholders to tender their shares in response to the pending tender offer by Harmony Biosciences Holdings. Harmony is offering an up-front purchase price of $1.1059 per share plus one non-tradable contingent value right (CVR) per share. The maximum additional payment to shareholders is up to an additional approximately $2.5444 per share in cash. The Offer is conditioned upon more than 50% of the outstanding shares of Zynerba common stock being tendered. As of September 27, approximately 32.1% of Zynerba's outstanding shares of common stock were tendered. The Offer has been extended until October 10, 2023. The Zynerba Board unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
News

HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

Rhea-AI Summary
Harmony Biosciences Holdings, Inc. extends tender offer for Zynerba Pharmaceuticals, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Rhea-AI Summary
Zygel (ZYN002) achieved statistically significant and clinically meaningful improvements in multiple efficacy assessments in a Phase 2 trial for children and adolescents with 22q11.2 deletion syndrome. The treatment showed positive results in anxiety-related and other behavioral symptoms, with statistically significant improvements in various scales. Caregivers reported improvement in self-identified problems. Zygel was generally well-tolerated with mild adverse events. Further study is warranted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
clinical trial
-
News

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

Rhea-AI Summary
Harmony Biosciences announces agreement to acquire Zynerba Pharmaceuticals for $60 million in cash, with potential additional payments of up to $140 million based on milestones. Acquisition aims to develop treatment for Fragile X syndrome and other rare neuropsychiatric disorders. Zygel, Zynerba's lead asset, is currently being evaluated in a pivotal Phase 3 clinical trial for FXS. Transaction expected to close by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none
-
News

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
News

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Stock ZYNE logo
Zynerba Pharmace

Nasdaq:ZYNE

ZYNE Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ZYNE Stock Data

70.12M
52.79M
6.07%
12.13%
0.78%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Devon